Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + olodaterol versus fluticasone propionate + salmeterol crossover study in COPD
NL-OMON38897Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiotropium, olodaterol, fluticasone propionate and salmeterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: FEV1 AUC 0-12h response after 6 weeks treatment. Started Dec 2013; status: active, not recruiting.
02
Drugs
tiotropiumolodaterolfluticasone propionatesalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON38897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38897.